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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal disease due to motoneuron
degeneration. Magnetic resonance imaging (MRI) is becoming a promising non-invasive
approach to monitor the disease course but a direct correlation with neuropathology is not
feasible in human. Therefore in this study we aimed to examine MRI changes in relation to
histopathology in two mouse models of ALS (C57BL6/J and 129S2/SvHsd SOD1G93A
mice) with different disease onset and progression. A longitudinal in vivo analysis of T2
maps, compared to ex vivo histological changes, was performed on cranial motor nuclei. An
increased T2 value was associated with a significant tissue vacuolization that occurred prior
to motoneuron loss in the cranial nuclei of C57 SOD1G93A mice. Conversely, in 129Sv
SOD1G93A mice, which exhibit a more severe phenotype, MRI detected a milder increase
of T2 value, associated with a milder vacuolization. This suggests that alteration within
brainstem nuclei is not predictive of a more severe phenotype in the SOD1G93A mouse
model. Using an ex vivo paradigm, Diffusion Tensor Imaging was also applied to study
white matter spinal cord degeneration. In contrast to degeneration of cranial nuclei, alter-
ations in white matter and axons loss reflected the different disease phenotype of
SOD1G93A mice. The correspondence between MRI and histology further highlights the
potential of MRI to monitor progressive motoneuron and axonal degeneration non-inva-
sively in vivo. The identification of prognostic markers of the disease nevertheless requires
validation in multiple models of ALS to ensure that these are not merely model-specific.
Eventually this approach has the potential to lead to the development of robust and vali-
dated non-invasive imaging biomarkers in ALS patients, which may help to monitor the effi-
cacy of therapies.
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Introduction
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized
by the loss of upper motoneurons in the cortex, as well as lower motoneurons in the brainstem
and spinal cord. In some cases, the first symptoms are misinterpreted, with the diagnosis of
ALS based on clinical criteria occurring more than a year later. The heterogeneity of the clinical
presentation of ALS, with respect to diversity of symptoms at onset, as well as the severity and
progression of the disease, further complicates diagnosis and prognosis. Even in families with
specific gene mutations, clinical heterogeneity is evident in the age and site of symptom onset,
as well as disease progression [1].
Specific and sensitive biomarkers of ALS pathology using non-invasive analytical tools
that could identify patients at the symptom onset are therefore essential to provide a faster
diagnosis and provide a means to classify patients for clinical trials of novel therapeutics.
Indeed, diagnostic imaging techniques, such as positron emission tomography, single photon
emission computed tomography and magnetic resonance imaging (MRI), afford a serial
assessment of pathology in the brain and the spinal cord of patients during the disease course
and are hence valuable to document pathological changes [2]. The widespread availability,
anatomical resolution and diversity of information obtainable by MRI position it as a promis-
ing tool to uncover region-specific biomarkers. At present, MRI is clinically mostly used for
differential diagnosis to exclude other “ALS-mimicking” syndromes [3]. However, due to the
heterogeneity of the clinical presentation of ALS and the diverse time courses, it is challenging
to develop and validate biomarkers purely based on the patient population. The use of animal
models therefore is an important investigative tool to establish and validate MRI-based bio-
markers [4].
A familial form of ALS can be modeled in transgenic mice by overexpressing multiple copies
of the human mutant SOD1 gene [5]. This model recapitulates several features of ALS, notably
a progressive loss of lower motor neurons and axons of the ventral motor roots leading to mus-
cle atrophy, paralysis, and eventually death [6–8]. Remarkable differences in the severity of dis-
ease phenotype have been noted in SOD1G93A mice, depending not only on transgene copy
number [9], but also and in particular on their genetic background [10–12]. In fact, we
observed that transgenic SOD1G93A mice in distinct inbred strains, namely C57BL/6J and
129S2/SvHsd (129SV), differed remarkably in disease progression and life span [13], as well as
their response to treatment with lithium and omega-3 polyunsaturated fatty acids [14, 15]. We
also identified marked differences in the motor neuron transcriptome between these two ALS
mouse models, as indices of fast and slow disease progression, which may prove useful in iden-
tifying potential disease modifiers responsible for the heterogeneity of human ALS [16].
The availability of strong magnetic field has allowed the application of MRI also in rodent
models of neurological disease, affording validation of MRI changes by histopathology. Indeed,
MRI has been used to document brain atrophy and an increase in tissue degeneration in
SOD1G93A mice [17–22]. However, it remains unclear if these changes precede or follow the
loss of brainstem motoneurons and how these alterations relate to disease state [23–25].
We therefore aimed to determine the potential of multimodal MRI of the brainstem and
lumbar spinal cord to discriminate between two SOD1G93A mouse models of ALS with differ-
ent rate of disease progression. We identified changes in cranial nuclei (as T2 relaxation time)
and in white matter spinal cord (as diffusion tensor imaging) between the two SOD1G93A
mouse strains. For validation of putative MRI biomarkers, histological studies have been per-
formed to determine the extent of nuclei degeneration and axonal disruption in these ALS
mouse models.
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Materials and Methods
Ethical statement
All the experiments and the protocol proposed in the projects were examined and approved
first by Institutional Animal Care and Use Committee (IACUC) and then authorized by the
Italian Ministry of Health (Decreto n 35/2012-B). Procedures involving animals and their care
were conducted according to the Mario Negri’s institutional guidelines that are in compliance
with national (D.L. no. 116, G.U. suppl. 40, Feb.518, 1992, Circular No.8, G.U., 14 luglio 1994)
and international laws and policies (EEC Council Directive 2010/63/UE). The mice were bred
and maintained in a SPF environment. Animals were monitored weekly for motor impair-
ments and changes in body weight. Animals with motor impairment had pellet and powdered
food in a petri dish on the cage bottom and water bottles with long drinking spouts. When the
animals were unable to right themselves within 10 s after being placed on either side, they were
humanely euthanized by deep anesthesia with Equithesin. Mice were then sacrificed by decapi-
tation followed by the dissection of tissues or underwent intracardiac perfusion to obtain tis-
sues for immunohistochemistry. This humane end point was defined as survival length. If
animals suffered infections and showed a sudden weight loss greater than 20% in one week,
they were euthanized by CO2 asphyxiation. During the entire period of MRI acquisition (45
min for each mouse), animals were maintained under gaseous anesthesia.
Transgenic animals
Female transgenic mice modeling ALS expressed ~20 copies of the mutant human gene SOD1
with a Glycine to Alanine substitution in position 93 (SOD1G93A mice) [5] either on C57BL/
6J strain (B6.Cg-Tg(SOD1G93A) 1Gur/J, Jackson Laboratories, here indicated as C57
SOD1G93A) or on 129S2/SvHsd strain (129Sv SOD1G93A) generated in house [14]. Trans-
genic mice were identified by PCR performed on DNA from tail biopsies. Samples were
completely digested by overnight incubation at 55°C in Direct-PCR lysis Buffer (Viagen Bio-
tech, Los Angeles, California, USA) containing 0.1μg/μl of Proteinase K (Promega). The follow-
ing day, they were incubated at 85°C for 30 minutes, to inactivate the Proteinase K, and then
analyzed by PCR. 50ng of DNA from each animal were used as a substrate for qualitative PCR,
in a mix containing 1x PCR buffer, GoTaq polymerase (0.25U), deoxyNTPs (250 μM each),
specific forward and reverse primers (0.5μM each) in a final volume of 10μl. All reagents were
purchased by Promega, except for primers that were synthesized by Life Technologies. Mice
were housed under standard conditions (22 ± 1°C, 60% relative humidity, 12 hour light/dark
schedule, 3–4 mice/cage, with free access to food and water). Although expressing the same
amount of transgene copies, C57 and 129Sv mice display a very different disease phenotype in
terms of disease onset (15.9 ±1.0 in C57 and 14.5 ±0.6 in 129Sv mice) (mean±SD) and survival
(24.2±1.8 in C57 and 17.8±0.8 in 129Sv mice) (S1 Fig). The different phenotype is well
described and it has previously been reported in several publications [13–15].
Experimental Design
Animals were randomly assigned to two different experiments: 1. In vivo serial T2-weighted
MRI acquisitions and 2. Ex vivo time course DTI and histopathological analyses. In both exper-
iments, transgenic mice were compared with their respective non-transgenic (Ntg) littermates.
Animals assigned to in vivo analysis of T2 relaxation time of brainstem were monitored for
disease progression using grip strength test (see below) (Fig 1). In vivo data acquisition started
at 7 weeks of age in both strains as a baseline and then followed at different time points during
the disease progression. In Fig 1 the differences in the disease progression between the two
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strains are shown, starting from the disease onset (Fig 1C), which corresponds to the first time
point at which the mice are unable to maintain the grip to the grid for at least 90 seconds. The
different time points of the MRI analysis are indicated by arrows in the graphs for each of the
two SOD1G93A mouse strains. For the in vivo analysis, the C57SOD1G93A mice were exam-
ined at 11, 15, 19 and 22 weeks of age corresponding to the pre-symptomatic, onset, symptom-
atic and advanced stage. The 129Sv SOD1G93A mice were examined only at the 11, 14 and 16
weeks of age, corresponding to pre-symptomatic, onset and advanced stage of the disease. The
intermediate stage of 15 weeks was not included in this analysis to avoid subjecting the mice to
frequent anaesthesia for in vivo MRI analysis.
For the histopathology of the brainstem, C57 mice were sacrificed at 11, 15, 19 and 22 weeks
as representative of pre-symptomatic, onset, symptomatic and advanced stage, respectively,
while 129Sv mice were examined only at 16 weeks of age when there was a small but significant
effect in T2. Instead, for ex vivo DTI analyses, both strains were analysed at the onset, symp-
tomatic and advanced stage of the disease, corresponding to 15, 19 and 22 weeks for C57 mice
and 14, 15 and 16 weeks for 129Sv mice. The same tissues of the ex vivo DTI were used for the
histopathology of the spinal cord and the count of axons in white matter.
Grip strength measurement
Briefly, for the grip strength test, animals were placed on a horizontal grid at about 30 cm
from the table and the tail was gently pulled until they grabbed the grid with their fore and
hind paws. The grid was then gently inverted and the latency time of the mouse to fall on the
table was recorded for a maximum of 90 sec. The test was repeated three time with at least 5
min of rest between each and the maximum time of latency was recorded. The onset of motor
symptoms was determined by the inability of mice to complete the grip strength test in 90 sec
in two consecutive sessions. By these analysis we confirmed an onset of symptoms of C57
SOD1G93A mice (n = 6) at 15.6 ±0.8 weeks of age (mean body weight 18.8g ± 1.2), while
129Sv SOD1G93A mice (n = 5) show the onset of motor impairment at 13.8± 0.4 weeks (mean
body weight 21.2g ± 0,4) (Fig 1C). These data are very similar to those obtained from the over-
all SOD1G93A mouse strains (S1A Fig) [13–15], confirming the low variability in disease phe-
notype of our colonies.
Fig 1. Disease progression in C57 and 129Sv SOD1G93Amice.Grip strength measurements of C57 SOD1G93A (A) and 129Sv SOD1G93A (B) mice
analysed in vivo for T2 relaxation time. Time points of MRI and histological studies are reported as arrows in correspondence to the respective ages of
analysis: ON = Onset, SS = symptomatic, AS = advanced stage. (C) Disease onset of C57 SOD1G93A (15.6 ± 0.8) and 129Sv SOD1G93Amice (13.8 ± 0.4)
analysed with T2 MRI. Statistical analysis: Student’s t-test. ** = p-value<0.01. Data are expressed as mean ± SD. N = 6 animals for C57 SOD1G93Amice
and 5 animals for 129Sv SOD1G93A mice.
doi:10.1371/journal.pone.0132159.g001
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Magnetic Resonance Imaging (MRI)
MRI acquisition was performed on a 7T small bore animal Scanner (Bruker Biospec, Ettlingen,
Germany), equipped with a BGA 12 gradient system (400 mT/m, rise time 110 μs). Two
actively decoupled radio frequency coils were used: a volume coil of 7.2 cm diameter used as
the transmitter and an anatomically shaped quadrature surface coil as the receiver.
In vivo T2-weighted MRI acquisition
For T2-weighted analysis, C57 SOD1G93A (n = 6) and 12Sv SOD1G93A (n = 5) mice were
used and compared to three respective non-transgenic littermates. Mice were anesthetized with
3–4% isoflurane (in 70:30 N2O:O2; v:v) and maintained under anesthesia with 1.0–1.5% iso-
flurane. Mice were secured using a head-holder with stereotaxic ear bars to reduce motion arti-
facts. Temperature was maintained at 37±0.5°C by a feedback controlled water circulating
heating cradle. Respiratory rate was monitored to maintain the depth of anesthesia during the
MRI scanning. Sagittal T2 maps of SOD1G93A and Ntg mice were acquired. For anatomical
orientation, 6 axial and 10 coronal T2-weighted slices were acquired using a spin echo sequence
with rapid acquisition with refocused echoes (RARE, TR 2000 ms, TE 12 ms, 1 average, field of
view (FOV) 20 x 20 mm with 256 x 256 matrix and slice thickness of 1 mm). To generate sagit-
tal T2 maps, a 20 echo train (ET) was acquired with the following parameters: TR 2500 ms, ini-
tial TE 11 ms, TE increment 11 ms, FOV 20 x 15 mm with 256 x 198 matrix and slice thickness
of 0.8 mm, 45 minutes scanning time.
T2 relaxation measurements
For the analysis and the quantification of T2 relaxation time in brainstem nuclei, the free soft-
ware ImageJ has been used. T2 maps were generated by linear fitting of the decay curve of 20
echoes. Regions of Interest (ROIs) were drawn corresponding to the facial nucleus, the trigemi-
nal nucleus and the inferior colliculus, according to a reference atlas (Allen brain Atlas) (Fig
2A). The exact localization of trigeminal and facial nuclei was determined in a mouse at the
advanced stage that showed a clear hyperintensity in both nuclei. This allowed defining and fix-
ing the distance between trigeminus and facialis in order to identify a combined ROI. Then, for
each mouse the combined ROI was adjusted in correspondence to the facial nucleus (easy to
recognize due its location in the ventral part of the hindbrain, between the caudal pons and the
rostral medulla) followed by the identification of the trigeminal ROI. The ROI inferior collicu-
lus, situated in the dorsal part of the brain (between the cerebellum and the cortex), was used
as a negative control region.
Ex vivo Diffusion Tensor Imaging (DTI) acquisition
In vivo DTI of a mouse spinal cord remains challenging due to prohibitive acquisition times, as
well as movement artefacts. To afford an adequate acquisition DTI was therefore acquired ex
vivo. Diffusion anisotropy has been demonstrated to be unaffected by fixation and preserve
inherent regional characteristics [26].
For DTI analysis, four animals per group at each stage were analyzed. Mice were perfused
with ice cold 0.1M PBS followed by 4% paraformaldehyde. To preserve the natural shape and
morphology of the spinal cord, the cords were kept inside the vertebral columns and were
immersed in the same fixative overnight at 4°C, then transferred to PBS. Before MRI imaging,
each spinal cord was covered with a plastic wrap and then embedded in agarose gelatin (1:5 in
H2O) within a 2.5 cm diameter plastic MR-compatible test tube. The surface coil was placed
over the lumbar tract of the spinal cord. Slices for DTI (Spin Echo, TR = 5000 ms, TE = 38.4 ms,
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Fig 2. T2 relaxation time of brainstem nuclei of SOD1G93Amice at different stages of the disease. (A) Representative T2-weighted images are shown
from a SOD1G93A (G93A) and a non-transgenic (Ntg) mouse. The ROIs correspondent to facial nuclei are indicated by a white arrow, to the trigeminal nuclei
are indicated by a white arrowhead and to the inferior collliculi are indicated by a black arrow. T2 relaxation times of facial (B, E) and trigeminal (C, F) nuclei
and of inferior colliculus (D, G) have been analyzed in C57 (B, C, D) and 129Sv (E, F, G) mice. SOD1G93A and non-transgenic mice have been compared
during the progression of the disease for each strain. EPS = early pre-symptomatic stage, PS = pre-symptomatic stage, ON = Onset, SS = Symptomatic
stage, AS = advanced stage. Data are expressed as mean ± SD. Statistical analysis: Two-way ANOVA, followed by Bonferroni’s post-hoc test. Facial
nucleus: in C57 mice genotype [F (1,7) = 623.8, p<0.0001], stage [F (4,28) = 52.82, p<0.0001] and interaction [F (4,28) = 52.86, p<0.0001], while in 129Sv
genotype [F (1,6) = 14.52, p = 0.0089], stage [F (3,18) = 2.481, p = 0.0939] and interaction [F (3,18) = 2.869, p0.0652]. Trigeminal nucleus: in C57 mice
genotype [F (1,7) = 72.81, p<0.0001], stage [F (4,28) = 15.99, p<0.0001] and interaction [F (4,28) = 18, p<0.0001]. Inferior Colliculus: genotype [F (1,7) =
0.5181, p = 0.495], stage [F (4,28) = 2.329, p = 0.0806] and interaction [F (4,28) = 0.4251, p = 0.7892], while in 129Sv genotype [F (1,6) = 4.081, p = 0.0899],
stage [F (3,18) = 0.5146, p = 0.6774] and interaction [F (3,18) = 3.294, p = 0.0443]. Stars indicate: * = p-value<0.05, ** = p-value<0.01, # = p-value<0.001.
6–5 animals in the SOD1G93A and 3 animals in the Ntg groups.
doi:10.1371/journal.pone.0132159.g002
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1 Average, 5 B0, 30 directions with b-value = 800 s/mm2, δ = 12 ms, Δ = 22ms, FOV 20x20mm,
256x256 matrix, in plane resolution 0.078 mm, 10 coronal slices at 1 mm thickness, 12.5h) were
aligned perpendicularly to the spinal cord axis, with the first slice at the intersection of the verte-
bral column and the second last rib.
DTI image analysis
After the ex vivo acquisition of the lumbar spinal cord by DTI, specific ROI were traced in
order to surround the whole section or specific regions of the spinal cord on trace weighted
images. Fractional anisotropy (FA), axial diffusivity and radial diffusivity were calculated using
MedInria (Asclepios Research Project—Inria Sophia Antipolis, http://www-sop.inria.fr/
asclepios/). ImageJ (http://rsbweb.nih.gov/ij/) was used to trace free hand ROIs in the white
matter: dorsal white matter (dWM), dorso-lateral white matter (dlWM), ventro-lateral white
matter (vlWM) and ventro-medial white matter (vmWM).
Histopathological analyses
For histopathological analyses, parallel groups of SOD1G93A mice were sacrificed at different
disease stages corresponding to those examined by MRI. Mice were transcardially perfused
with 50 ml of 0.1M PBS followed by 50 ml of 4% paraformaldehyde. As previously described
[14], brains and spinal cords were serially sectioned on a cryostat at -20°C (20μm) in a coronal
plane. Every fourth brain section was processed with Cresyl Violet (Nissl staining) for neuronal
counting. For each group (n = 4), 9 and 12 sections were analyzed for trigeminal or facial
nucleus, respectively.
Adjacent sections were stained with Haematoxylin and Eosin (H&E) for a better qualitative
assessment of the tissue vacuolization.
Nissl staining
For Nissl staining, slides were de-hydrated and re-hydrated in a series of alcohols. Slides were
then immersed in cresyl-violet 0.5% solution in water for 3 min, washed and moved to 96%
ethanol solution. Slides were then dipped for 1 min in 3% acetic acid solution in ethanol to
remove the excess of Cresyl Violet. Then slides were placed in absolute ethanol and in xylene,
before being coverslipped with DPX mounting medium (BDH, Poole Dorset, UK). Nissl
stained samples were acquired at a 10x magnification under an Olympus BX61 light micro-
scope and images of the trigeminal and facial nuclei were collected with a camera, using the
AnaliSYS software (Soft Imaging Systems, ver. 3.2). Clear stained motor neurons, displaying a
dark nucleolus and a clear nucleus, were counted using ImageJ. Since we count neurons every
forth sections, the final counts were then multiplied by four, in order to estimate roughly the
total number of neurons in the nuclei, as reported by Haenggeli et al. [23]. Four mice per group
were analyzed.
Haematoxylin & Eosin (H&E) staining
Since it was difficult to clearly identify the vacuolated parenchyma around neurons with Nissl
staining, we decided to perform the H&E staining on adjacent sections. Briefly, sections were
dipped in Hematoxylin solution (1% Hematoxylin, 5% aluminum potassium sulfate, 0.02%
sodium iodate, 5% chloral hydrate and 1% citric acid, in distilled water) for 3 minutes. After a
wash in running tap water, sections were placed in Eosin solution (Eosin 1% in distilled water)
for 1 minute. Sections were then washed in running tap water and dehydrated through a
graded series of ethanol. Finally, the sections were fixed in Xylene before being coverslipped
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using DPX mountant (BDH, Poole Dorset, UK). Slides were examined by an operator unaware
of the animal group in order to give a qualitative evaluation of the presence or not of vacuoles
in all sections. Four mice per group were analyzed.
SMI-31 immunohistochemistry
Coronal sections of the L2 segment of the spinal cord were stained with SMI-31 marker, which
allows the detection of phosphorylated neurofilaments that compose axons and is therefore
considered a marker of axonal integrity. Free-floating sections were first treated with H2O2 1%
in PBS 0.01 M for 10 minutes to inhibit endogenous peroxidases. Then, they were incubated
for 1 h at room temperature (RT) in a blocking solution containing normal goat serum 10% in
PBS. Samples were incubated overnight at 4°C with the primary monoclonal antibody against
SMI-31 [1:7500] (Covance), diluted in PBS containing normal serum 1%. The day after, sec-
tions were probed with the corresponding secondary biotinylated antibody (1:200, Vector
Labs) in 1% normal serum and PBS for 1 hour. After 3 washes, sections were immersed in avi-
din-Biotin peroxidase solution (Vectastain kit, Vectro labs) for 1 hour. Immunohistochemistry
was revealed by the reaction with 3’-3-diaminobenzidine tetrahydrochloride (DAB, 0.5 mg/ml
in TBS + hydrogen peroxide at a final concentration of 0.009%). Subsequently sections were
washed, mounted on gelatine-covered glass slides and dried overnight at room temperature.
The day after sections were dehydrated through a graded series of alcohols, fixed in Xylene and
cover slipped using DPX mountant (BDH, Poole Dorset, UK). SMI-31 stained sections were
acquired at a 40x magnification under an Olympus BX61 light microscope.
Axons quantification
Axons of the L2 segment of the lumbar spinal cord were counted at a magnification of 40x, in
serial sections, using the free software ImageJ. 3 animals per each group have been analysed. As
SMI-31 positive axons were readily identified, it was possible to isolate these using a threshold
based on their higher grey values. Using the free software ImageJ, each axon separately was
counted using the command ‘Analyse particles’. For each animal, we analysed two 30μm thick
sections, sampled in the L2 segment and distanced one from another 600 μm. The count of
axons of the two sections was averaged and the resulting number was used for statistical
analysis.
Statistical Analysis
The analysis of MRI images and the quantification of neurons, vacuoles and white matter
axons count were performed blinded. For the longitudinal measure of T2 and for the analysis
of ex-vivo DTI parameters a two-way ANOVA followed by Bonferroni’s post-hoc test was
applied for the comparison between Ntg and SOD1G93A mice. For the motor neurons count,
a two-way ANOVA or Student’s t-test was used as appropriate.
Results
Analysis of cranial nuclei degeneration
C57 SOD1G93A mice developed a delayed onset of motor symptoms and a slower disease pro-
gression compared to 129Sv mice despite expressing the same amount of human SOD1 trans-
gene products. In fact, disease duration was more than doubled in C57 SOD1G93A with
respect to 129Sv mice (8.3 ±2.1 vs 3.2 ± 0.6 weeks, respectively) (Fig 1).
Serial in vivo MRI was applied to sagittal sections of brain from the two ALS mouse models
at different times during the course of the disease to examine signal changes inside different
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nuclei of the brainstem as potential markers of disease onset and progression (Fig 2). In C57
SOD1G93A mice the T2 relaxation time in the facial nucleus (Fig 2B) and trigeminal nucleus
(Fig 2C) was significantly higher compared to non-transgenic littermates. Even in the pre-
symptomatic stage, a significant difference in the facial nucleus was already evident and pro-
gressively increased during the disease course. In contrast, the trigeminal nuclei exhibited the
first significant increase concomitant with the onset of motor symptoms. Interestingly, this sig-
nal change did not further increase with disease progression. Conversely, the 129Sv
SOD1G93A mice showed no differences in T2 relaxation time of the cranial nuclei until the
advanced stage of the disease (Fig 2E and 2F). However, even at this stage, the T2 increase in
the facial and trigeminal nuclei was much lower compared to C57 SOD1G93A mice. These
changes were nuclei specific, as no change in T2 was evident in the inferior colliculus (Fig 2D
and 2G), which served as an internal control in this study, since it is an unaffected region.
The neuron counts in both cranial nuclei of C57 SOD1G93A mice exhibited no differences
with respect to non-transgenic littermates at the pre-symptomatic and onset stages of the dis-
ease. The first sign of neuronal loss emerged at the symptomatic stage only in the trigeminus
(19% reduction) while in the facial nucleus there was only a trend (14% reduction, p>0.05). At
the advanced stage of the disease, a significant 37% and 47% decrease of neurons was detected
for facial and trigeminal nuclei, respectively (Fig 3A and 3L). Nevertheless, structural changes
in the parenchyma around motor neurons were observed in C57 SOD1G93A mice at an earlier
stage compared to the Ntg littermates (Fig 3G and 3R). In particular, at the pre-symptomatic
and onset stage of the disease, small vacuoles in facial and trigeminal nuclei were observed (Fig
3H-3I and 3T) despite no motor neuron loss. These vacuoles further increased with disease
progression. At the symptomatic (Fig 3J and 3U) and advanced stage (Fig 3K and 3V), the
parenchyma in both facial and trigeminal nuclei was covered by numerous large vacuoles.
Conversely, the histopathological analysis of 129Sv SOD1G93A mice, at the time in which
the T2 increase was observed (advanced stage, Fig 2E and 2F), revealed a slight decrease (20%,
p = 0.0022) of the neurons count of the facial nucleus, while the trigeminus did not show neu-
ronal loss even at the advanced stage of the disease (p = 0.86, Fig 4A and 4F). At this stage
some extracellular vacuoles were present in the cranial nuclei of 129Sv SOD1G93A mice (Fig
4E and 4J), compared to Ntg littermates (Fig 4D and 4I). However, the vacuolization appeared
at a much lower degree in the trigeminus nucleus than in the facial nucleus, which is in accor-
dance with the milder alteration in the T2 relaxation time found in the trigeminus.
White matter (WM) degeneration in spinal cord
The lumbar portion of the spinal cord was examined for WM degeneration by ex vivo diffusion
tensor imaging (DTI) (Fig 5). Spinal cords of Ntg mice revealed no signal changes between dif-
ferent time points (data not shown). In contrast, both C57 SOD1G93A and 129Sv SOD1G93A
mice exhibited a progressive decrease of FA and axial diffusivity over time (Fig 5A), whereas
radial diffusivity increased (S2 Fig). While overall DTI alterations of the WM were evident at
the advanced stage of the disease in both C57 SOD1G93A and 129Sv SOD1G93A compared to
respective non transgenic mice, differences were observed between the two mouse models at
earlier disease stages. In fact, a decreased axial diffusivity was detected in the ventro-lateral and
dorsal WM regions of 129Sv SOD1G93A mice with respect to non transgenic mice, already at
the onset of the disease (Fig 5Ad and 5Ah) while in C57 SOD1G93A mice this phenomenon
was evident only at the advanced stage. The decrease of axial diffusivity partially overlapped
with the reduction in the axons count of the spinal cord white matter in the two SOD1G93A
mouse strains. In fact, with the exception of the ventro medial region in which the reduction of
axons found in both SOD1G93A mouse strains at the symptomatic stage did not reflect a
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Fig 3. Evaluation of cranial neuron number and their vacuolization in C57 SOD1G93Amice and non-transgenic littermates. Facial (A-K) and
trigeminal (L-V) nuclei have been analyzed by Nissl (B-F, M-Q) and H&E (G-K, R-V) staining to quantify brainstem neurons and to detect vacuolization,
respectively. (A) Neuronal cell count of facial nucleus of C57 SOD1G93Amice at different disease stages and relative non-transgenic littermates. (B-F) Nissl
staining microphotographs of the facial nucleus of non-transgenic (Ntg, B) and SOD1G93A (C-F) C57mice at pre-symptomatic (C), onset (D), symptomatic (E)
and advanced stage (F) of the disease. G-K: H&E staining microphotographs of the facial nucleus of non-transgenic (Ntg, G) and SOD1G93A (H-K) C57 mice at
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pre-symptomatic (H), onset (I), symptomatic (J) and advanced stage (K) of the disease. (L) Neuronal cell count of trigeminal nucleus of C57 SOD1G93Amice at
different disease stages and relative non-transgenic littermates. M-Q: Nissl staining microphotographs of the trigeminal nucleus of non-transgenic (Ntg, M) and
SOD1G93A (N-Q) C57mice at pre-symptomatic (N), onset (O), symptomatic (P) and advanced stage (Q) of the disease. (R-V) H&E staining microphotographs
of the trigeminal nucleus of non-transgenic (Ntg, R) and SOD1G93A (S-V) C57mice at pre-symptomatic (S), onset (T), symptomatic (U) and advanced stage
(V) of the disease. Scale bars represent 100 μm in Nissl microphotographs (B-F, M-Q) and 200 μm in H&Emicrophotographs (G-K, R-V). PS = pre-symptomatic
stage, SS = Symptomatic stage, AS = advanced stage. The total neurons number was obtainedmultiplying the raw counts by four to give an estimate of the
total cell number in the nucleus. Data are expressed asmean ± SD. Statistical analysis: Two-way ANOVA, followed by Bonferroni’s post-hoc test. Statistical
analyses revealed, for the facial nucleus, significant effects for genotype [F (1,6) = 26.59, p = 0.0021], for stage [F (3,18) = 4.486, p = 0.0161] and interaction [F
(3,18) = 6.298, p = 0.0041]. For the trigeminal nucleus, significant effects were revealed for genotype [F (1,6) = 152.8, p<0.0001], for stage [F (3,18) = 8.251,
p = 0.0012] and interaction [F (3,18) = 14.13, p<0.0001]. Stars indicate: * p-value<0.05, *** p-value<0,001 between SOD1G93A and respective Ntg littermates.
4 animals for each group.
doi:10.1371/journal.pone.0132159.g003
Fig 4. Evaluation of cranial neuron number and their vacuolization in 129Sv SOD1G93Amice and non-transgenic littermates. Facial (A-E) and
trigeminal (F-J) nuclei have been analyzed by Nissl (B-C, G-H) and H&E (D-E, I-J) staining to quantify brainstem neurons and to detect vacuolization,
respectively. (A) Neuronal cell count of facial nucleus of 129Sv SOD1G93A mice at the advanced stage of the disease and relative non-transgenic
littermates. (B-C) Nissl staining microphotographs of the facial nucleus of non-transgenic (Ntg, B) and SOD1G93A (C) 129Sv mice at the advanced stage of
the disease. (D-E) H&E staining microphotographs of the facial nucleus of non-transgenic (Ntg, D) and SOD1G93A (E) 129Sv mice at the advanced stage of
the disease. (F) Neuronal cell count of trigeminal nucleus of 129Sv SOD1G93Amice at the advanced stage of the disease and relative non-transgenic
littermates. (G-H) Nissl staining microphotographs of the trigeminal nucleus of non-transgenic (Ntg, G) and SOD1G93A (H) 129Sv mice at the advanced
stage of the disease. (I-J) H&E staining microphotographs of the trigeminal nucleus of non-transgenic (Ntg, I) and SOD1G93A (J) 129Sv mice at the
advanced stage of the disease. Scale bar represents 100 μm in Nissl microphotographs (B-C, G-H) and 200 μm in H&Emicrophotographs (D-E, I-J).
AS = advanced stage. The total neuron number was obtained multiplying the raw counts by four to give an estimate of the total cell number in the nucleus.
Data are expressed as mean ± SD. Statistical analysis: Student’s t-test. ** p-value<0.01 between SOD1G93A and respective Ntg littermates. 4 animals for
each group.
doi:10.1371/journal.pone.0132159.g004
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Fig 5. Diffusion Tensor Imaging (DTI) parameters and axonal count of lumbar spinal cord in C57 and 129Sv SOD1G93Amice during disease
progression. (A) On the left, representative images of the Fractional Anisotropy of the lumbar spinal cord have been reported. Different white matter regions
were took into consideration for the analyses: ventro-medial (vmWM), ventro-lateral (vlWM), dorso-lateral (dlWM) and dorsal (dWM). White lines represent
the white matter area taken into consideration. Different diffusion parameters have been considered for the analysis of white matter degeneration through
DTI: Fractional Anisotropy (a,c,e,g) and axial diffusivity (b,d,f,h). (B) The axonal count has been performed in the same white matter regions analysed with
DTI. SOD1G93Amice have been analyzed at the onset, symptomatic (Sympto) and advanced stage (AS) of the disease. Data are expressed as ratio
between SOD1G93A and their respective Ntg mice. Mean ± SD is reported. Statistical analysis: Two-way ANOVA has been used to compare Ntg and
SOD1G93Amice during the disease progression, followed by Bonferroni’s post-hoc test. Stars indicate: * p-value<0.05, ** p-value<0.01, *** p-
value<0.001, **** p-value<0.0001, between SOD1G93A and their respective Ntg controls of the same mouse strain. # indicates p-value<0.05 between C57
and 129Sv mice of the same disease stage. 4–3 animals for each group.
doi:10.1371/journal.pone.0132159.g005
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reduction in axial diffusivity, in all the other white matter regions of 129Sv SOD1G93A mice at
symptomatic and advanced stage of the disease, the variations of the two parameters over-
lapped (Fig 5A and 5B). A massive loss of SMI31 positive fibers was evident overall in the
white matter regions of both SOD1G93A mouse strain at the advanced disease stages (Fig 5B,
S3 and S4 Figs), where the axonal loss led to an increased extracellular and inter-axonal spacing
(S3 and S4 Figs).
Discussion
In this work, we evaluated the significance of MRI technique in detecting and predicting differ-
ences in two familial ALS mouse models with a different disease course. Indeed, despite these
mice expressing the same amount of SOD1G93A transgene and protein, their different genetic
background, C57 or 129Sv, influences both the onset of motor symptoms and the rate of dis-
ease progression.
We compared the cranial nuclei degeneration between these two fALS mouse models during
the disease course. This comparative analysis showed a different vulnerability of the cranial
motoneurons in the two ALS animal models. However, surprisingly, the 129Sv SOD1G93A
mice, with a faster disease progression, exhibited a remarkable delay in the alterations of these
nuclei by both MRI and histopathological analysis, compared to C57 SOD1G93A mice. In C57
SOD1G93A mice, the MRI analysis revealed an early and progressive increase of T2 relaxation
time of both facial and trigeminal nuclei, starting from the pre-symptomatic stage of the dis-
ease, as reported also by Evans et al. [22]. We demonstrated that this MRI alteration is mostly
associated with the formation of vacuoles, rather than motoneurons loss. Indeed, while T2
started to increase at the pre-symptomatic stage, when also vacuolization was detected, moto-
neurons loss was found only at a symptomatic stage of the disease, confirming previous results
[19, 23–25, 27, 28]. Our results corroborate data obtained in previous longitudinal studies,
where SOD1G93A mice displayed a significant higher T2 value in cranial nuclei, compared to
non-transgenic littermates [17, 20–22, 29]. The correspondence that we detected between a
higher T2 relaxation time and the vacuoles formation is in line with previous results obtained
by Bucher and co-workers [20]. Moreover, we demonstrated, for the first time, that these signal
alterations precede motoneuron loss, which occurs only later in the disease course. However,
the recent paper from Evans et al. questioned a causal relationship between vacuolization and
T2 increase, suggesting that also an increased astrocytosis and microgliosis correlated to a simi-
lar extent with T2 intensity [22]. Since in the present study we have not examined astroglia and
microglia in the brainstem of the two SOD1G93A mouse strains, we cannot exclude that the
differences found in T2 intensity in both facial and trigeminal nuclei may depend on different
reactive glial responses between the two mouse strains. Nevertheless, vacuole formation
remains one of the earliest signs of motor neuron alterations. In fact, vacuolization, which is
primarily due to abnormal and swollen mitochondria, has been observed as early as one month
of age in dendrites and proximal axons of spinal motoneurons [30, 31], before the loss of
motor neurons perikaria and the appearance of a glial reaction [6]. Here we reported a clear
vacuolization at the level of neuropil of cranial motor nuclei of C57 SOD1G93A mice already
at the pre-symptomatic stage and in particular at the onset of motor symptoms and later on.
As for the spinal motor neurons, the presence of vacuoles in the cranial motor nuclei, detected
by electron and light microscopy [20, 32], does not depend on, but precedes, the motor neuron
loss. However, even at a pre-symptomatic stage, i.e. asymptomatic for hind limb motor dys-
function, preliminary signs of dysfunction can be appreciated by measuring licking and masti-
cation rates [33]. For this reason, a method such as in vivo MRI, that can visualize non-
invasively the tissue degeneration in cranial nuclei, could be useful for the monitoring of motor
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function impairment associated with these nuclei. With respect to this, our T2 analysis is in
accordance with the results presented by Evans and colleagues [22]. Indeed, our results confirm
the high sensitivity and specificity of T2 relaxation time in detecting abnormalities even before
motoneurons loss, supporting T2 imaging as an early biomarker of the disease. The fact that
we observed a higher increase of T2 relaxation time in facial rather than in trigeminal nucleus,
is also in line with that reported by Evans and co-workers [22] and can be due to the lower
thickness of the latter nucleus (~0.5 mm, compared to ~1 mm of the facial nucleus). This
might have influenced the level of signal acquired from 0.8 mm thick slices, i.e. the signal from
the trigeminal nucleus could be affected by partial volume effects.
An interesting, if surprising, result of this study is the fact that the 129Sv SOD1G93A mice,
with a faster disease progression, exhibited a remarkable delay in the alterations of the cranial
nuclei detected by both MRI and histopathological analysis, as compared to C57 SOD1G93A
mice. In fact, this suggests that the degeneration of brainstem nuclei is not predictive of a more
severe phenotype in the SOD1G93A mouse models. Recently, the comparative analysis of the
spinal cord and motor neurons of these two SOD1G93A mouse strains highlighted differences
associated with the disease severity which were unrelated to the degree of motor neuron loss
[13]. In fact, the loss of motor neurons was similar two weeks after the symptom onset in both
the slow and fast progressing ALS mouse model. However, an earlier accumulation of ubiquiti-
nated protein aggregates was found in the motor neurons of the 129Sv SOD1G93A compared
to C57 SOD1G93A mice clearly indicating a dysfunction of remaining motor neurons [13]. A
differential vulnerability of cranial motoneurons among different MND animal models has
already been reported [23], suggesting that there is a selective motoneuron loss in this region
which depends upon the particular mouse model and disease stage. However, since 129Sv
SOD1G93A mice die much earlier than the C57 SOD1G93A mice we cannot exclude that the
preservation of their brainstem motor neurons is only due to the premature death of these
mice rather than their different vulnerability.
Besides brainstem degeneration, axonal loss and dysfunction are also hallmarks of ALS.
Whereas the loss of motor neurons perikarya leads to morphological alterations in the grey
matter, the consequent loss of axons results in the degeneration of the white matter.
Conversely to the degeneration of cranial nuclei, the alterations of the axonal pathways,
detected in spinal cord white matter by DTI analysis, changes in relation to the different disease
phenotype of SOD1G93A mice. In fact, the 129Sv SOD1G93A mice exhibited a lower axial dif-
fusivity in both ventrolateral and dorsal WM regions, already at the onset of the disease, while
the same parameter in C57 SOD1G93A mice decreased only at the advanced stage with refer-
ence to respective non transgenic mice. Such difference was confirmed by histological ex vivo
analysis, as demonstrated by the reduced SMI-31 positive axon density in these regions of
129Sv SOD1G93A mice at the disease onset. It should be noted that these regions are crossed
by the axons of spinal and cortical motor neurons, respectively. We recently demonstrated that
the different phenotype of the these two SOD1G93A mice strains is not due to a different
motor neuron loss in the lumbar spinal cord but rather to a difference in their function, i.e. ubi-
quitinated aggregates accumulation [13]. With the present study, we demonstrate that the two
mouse strains remarkably differ in their axonal degeneration as demonstrated by both DTI and
histopathological analysis of the white matter. Interestingly, our recent studies on the extent of
muscle denervation of these two mouse models support this observation (manuscript submit-
ted). Therefore, we hypothesize that a decreased axial diffusivity by DTI analysis can be a good
indicator of an axonal damage at early disease stages [34, 35]. This is in line with the observa-
tions reported by different studies [34, 36–38].
A worsening of these alterations was found at the advanced stage, when both FA and axial
diffusivity further decreased, mirroring a further axonal loss and degeneration. Moreover, at
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this stage, an increased radial diffusivity was observed (S2 Fig). This is probably due to the
increased inter axonal space associated to the reduced axonal density and/or function as indi-
cated by the reduction of SMI-31 staining [34, 39, 40]. Interestingly, we recently demonstrated,
through the analysis of the transcriptional profile of the laser-dissected motor neurons of
129Sv SOD1G93A mice at the disease onset, a marked down regulation of specific pathways
involved in the axonal transport mechanisms, i.e. neuron projection, microtubule and protein
transport categories, as an index of a prominent axonal dysfunction which was not detected in
C57 SOD1G93A mice at the same disease stage [16]. This supports the hypothesis that intrinsic
axonal mechanisms actively determine the phenotype in ALS (reviewed in [41]).
Recently, Evans et al. reported a diffusion analysis only of the brainstem region, reporting a
lower capacity of apparent diffusion coefficient (ADC) in differentiating between SOD1G93A
and Ntg mice, compared to T2 analysis [22]. Differently, analyzing the lumbar spinal cord by
DTI, we showed that this MRI technique has the potential to discriminate between different
disease severities, being more predictive of a severe disease phenotype in SOD1G93A mice
than T2 relaxation time of brainstem nuclei. Thus, we propose spinal cord DTI as a useful
marker to detect early alterations in the function of motor axons with respect to the motor phe-
notype of SOD1G93A mice even before the loss of motor neurons.
In ALS patients, the vast majority of studies analyzed the cortico spinal tract in the brain
and reported a decreased FA and an increased Mean Diffusivity in this area. However, the anal-
ysis of axial diffusivity is not always consistent, since some groups reported an increase [42],
some groups a decrease [37] and some groups a lack of changes [43–45]. In contrast, papers
reporting an analysis of ALS patients’ spinal cord consistently report decreased FA in the white
matter of the cervical tract [46, 47] with an increased radial diffusivity [48]. These data are in
line with our observations of spinal cord of SOD1G93A mice at the advanced disease stage
although a reduced FA was detectable also at the symptomatic stage in fast progressing mice.
In conclusion, our study demonstrates a differential regional motoneuron vulnerability
between two familial ALS mouse models. Surprisingly, the 129Sv SOD1G93A strain, although
having a more severe phenotype, displayed a delayed degeneration of cranial nuclei as com-
pared to the slowly progressing diseased mice confirming the later vulnerability of the brain-
stem motor neurons in these ALS mouse models. Moreover, we demonstrated that DTI
analysis may predict the severity of disease progression in ALS mice. This suggestion should
however be taken with caution as further studies are needed to confirm this interpretation of
data in order to propose the use of axial diffusivity to predict the disease severity.
The present study underlines, once again, the importance of the comparison between the
two mouse models in defining the molecular mechanisms that might eventually enable the
identification of prognostic markers of the disease and afford the design of targeted therapeutic
strategies for individual patients.
Supporting Information
S1 Fig. Disease phenotype of C57 and 129Sv SOD1G93A mice. Kaplan Meier plots showing
the proportion of transgenic mice without symptoms of disease onset (a) and percentage of
surviving animals (b) are reported. From graphs it is possible to appreciate the earlier onset
and the faster disease progression in 129Sv SOD1G93A mice, compared to C57 SOD1G93A
mice. Indeed, C57 SOD1G93A mice displayed first motor symptoms at 15.9 ±1 weeks of age
(mean body weight 20.5g ± 1.7) and died at 24.5 ±1.6 weeks (mean body weight 18g ± 1.7),
while 129Sv SOD1G93A mice show the onset of motor impairment at 14.5± 0.6 weeks (mean
body weight 17.2g ± 2.5) and they died at 17.8 ±0.8 weeks of age (mean body weight
14.1g ± 2.2). The statistical analysis by the Log-rank test reveals a p-value< 0.0001 for both
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onset and survival. (c) Weight change of C57 and 129Sv SOD1G93A mice during the disease
progressio. Data are expressed as mean ± SD. N = 15 animals for C57 SOD1G93A mice and 24
animals for 129Sv SOD1G93A mice.
(TIF)
S2 Fig. Radial Diffusivity of lumbar spinal cord in C57 and 129Sv SOD1G93A mice during
disease progression. Radial diffusivity of different white matter regions has been reported:
ventro-medial (vmWM, a), ventro-lateral (vlWM, b), dorso-lateral (dlWM, c) and dorsal
(dWM, d). On the left, representative images of the Fractional Anisotropy of the lumbar spinal
cord have been reported. The white line represents the white matter area taken into consider-
ation.
(TIF)
S3 Fig. Axonal degeneration in the white matter spinal cord of C57 SOD1G93A mice.
Microphotographs of SMI-31 staining of the lumbar white matter spinal cord are reported
from a non-transgenic (A-D) and C57 SOD1G93A mice at the onset (E-H), symptomatic (I-L)
and advanced stage (M-P) of the disease. In the first line boxes, a schematic representation of
the L2 coronal section is shown, with a grey square showing the white matter portion analysed:
vmWM (A, E, I, M), vlWM (B, F, J, N), dlWM (C, G, K, O) and dWM (D, H, L, P). Scale bar
50 μm.
(TIF)
S4 Fig. Axonal degeneration in the white matter spinal cord of 129Sv SOD1G93A mice.
Microphotographs of SMI-31 staining of the lumbar white matter are reported from a non-
transgenic (A-D) and 129Sv SOD1G93Amice at the onset (E-H), symptomatic (I-L) and
advanced stage (M-P) of the disease. In the first line boxes, a schematic representation of the L2
coronal section is shown, with a grey square showing the white matter portion analyzed: vmWM
(A, E, I, M), vlWM (B, F, J, N), dlWM (C, G, K, O) and dWM (D, H, L, P). Scale bar 50 μm.
(TIF)
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